• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Timber Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    1/26/24 8:00:46 AM ET
    $TMBR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TMBR alert in real time by email
    false --12-31 Timber Pharmaceuticals, Inc 0001504167 0001504167 2024-01-22 2024-01-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 22, 2024

     

    TREX WIND-DOWN, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-37411   59-3843182

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    3 Mountainview Road, Suite 100,

    Warren, NJ 07059

    (Address of principal executive offices)

     

    Registrant’s telephone number, including area code: (908) 636-7160

     

    TIMBER PHARMACEUTICALS, INC.

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    N/A   N/A   None

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

      
     

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On January 23, 2024, Trex Wind-down, Inc. (f/k/a Timber Pharmaceuticals, Inc.) (the “Company”) filed with the Secretary of State of the State of Delaware a certificate of amendment to the Company’s certificate of incorporation, as amended (the “Name Change Amendment”), in connection with the previously announced closing of the sale of substantially all of the assets of the Company and its subsidiaries on January 22, 2024 pursuant to the “stalking horse” asset purchase agreement by and among the Debtors (as defined herein), LEO Pharma A/S and LEO Spiny Merger Sub, Inc. The Name Change Amendment did not amend the certificate of incorporation except to change the corporate name from “Timber Pharmaceuticals, Inc.” to “Trex Wind-down, Inc.”, effective January 23, 2024.

     

    The foregoing description of the Name Change Amendment is not complete and is subject to, and qualified in its entirety by, the complete text of the Name Change Amendment which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 8.01 Other Events.

     

    As previously disclosed, on November 17, 2023, the Company and certain of its subsidiaries (the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the “Chapter 11 Case”). The Chapter 11 Case is being administered under caption and case number: In re: Timber Pharmaceuticals, Inc., et al., Case No. 23-11878.

     

    On January 22, 2024, the Company and the Debtors filed monthly operating reports with the Bankruptcy Court for the month ended December 31, 2023 (the “Monthly Operating Reports”). The Monthly Operating Reports are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 and are incorporated herein by reference.

     

    The Company will file, under cover of a Current Report on Form 8-K, its periodic financial reports filed with the Bankruptcy Court, as well as other material financial information concerning developments in its bankruptcy proceedings, in lieu of filing the Company’s annual and quarterly reports under the Securities Exchange Act of 1934 (the “Exchange Act”).

     

    Cautionary Note Regarding the Monthly Operating Reports

     

    The Company cautions investors and potential investors not to place undue reliance upon the information contained in the Monthly Operating Reports, which were not prepared for the purpose of providing the basis for an investment decision relating to any Company securities. The Monthly Operating Reports are limited in scope and have been prepared solely for the purpose of complying with requirements of the Bankruptcy Court. The Monthly Operating Reports were not reviewed by independent accountants, are in a format prescribed by applicable bankruptcy laws, and are subject to future adjustment. The financial information in the Monthly Operating Reports is not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), and, therefore, may exclude items required by GAAP, such as certain reclassifications, eliminations, accruals, valuations and disclosures. The Monthly Operating Reports also relate to a period that is different from the historical periods required in the Company’s reports pursuant to the Exchange Act.

     

    Cautionary Note Regarding Trading in the Company’s Securities

     

    The Company cautions that trading in the Company’s securities during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders of the Company’s securities in the Chapter 11 Case. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.

     

     

     

     

    Cautionary Note Regarding Forward-Looking Statements

     

    This Current Report on Form 8-K may contain forward-looking statements, including statements regarding the Chapter 11 Case and the Company’s ability to continue operating in the ordinary course while the Chapter 11 Case is pending, within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “potential,” “projects,” “target,” “will,” “would” and “future” or similar expressions are intended to identify forward looking statements. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, (i) potential adverse effects of the Chapter 11 Case on the Company’s liquidity and results of operations; (ii) the Company’s ability to obtain timely approval by the Bankruptcy Court of the motions filed in the Chapter 11 Case; (iii) employee attrition and the Company’s ability to retain senior management and other key personnel due to the distractions and uncertainties; (iv) the Company’s ability to maintain relationships with suppliers, customers, employees and other third parties and regulatory authorities as a result of the Chapter 11 Case; (v) the effects of the Chapter 11 Case on the Company and on the interests of various constituents, including holders of the Company’s common stock; (vi) the Bankruptcy Court’s rulings in the Chapter 11 Case and the outcome of the Chapter 11 Case generally; (vii) the length of time that the Company will operate under Chapter 11 protection and the continued availability of operating capital during the pendency of the Chapter 11 Case; (viii) risks associated with third party motions in the Chapter 11 Case; (ix) increased administrative and legal costs related to the Chapter 11 process; (x) exposure to potential litigation and inherent risks involved in a bankruptcy process; (xi) diversion of management’s attention from ongoing business operations and opportunities; (xii) potential adverse reactions or changes to business or employee relationships, including those resulting from the bankruptcy proceedings of the Company; (xiii) risks arising from the delisting of the Company’s common stock from The NYSE American, LLC; (xiv) risks relating to the Company’s attempts to confirm its Chapter 11 plan, including the risk that the Chapter 11 plan may not be accepted by the Company’s creditors or confirmed by the Bankruptcy Court; and (xv) other risks and uncertainties, including those described in the section entitled “Risk Factors” in the Company’s most recent annual or quarterly report filed with the Securities and Exchange Commission and in other filings the Company makes with the Securities and Exchange Commission from time to time. The forward-looking statements herein do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update the information contained in this Current Report on Form 8-K to reflect new events or circumstances, except as required by law.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    3.1   Certificate of Amendment of Certificate of Incorporation, as amended, of Trex Wind-down, Inc. (f/k/a Timber Pharmaceuticals, Inc.), dated January 22, 2024.
         
    99.1  

    Trex Wind-down, Inc. (f/k/a Timber Pharmaceuticals, Inc.), Monthly Operating Report for the month ended December 31, 2023, filed with the United States Bankruptcy Court for the District of Delaware.

         
    99.2   Trex Wind-down, LLC (f/k/a Timber Pharmaceuticals, LLC) Monthly Operating Report for the month ended December 31, 2023, filed with the United States Bankruptcy Court for the District of Delaware.
         
    99.3   BioPharmX Inc., Monthly Operating Report for the month ended December 31, 2023, filed with the United States Bankruptcy Court for the District of Delaware.
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

      
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      TREX WIND-DOWN, INC.
       
    Date: January 26, 2024 By: /s/ Jeffrey T. Varsalone
      Name: Jeffrey T. Varsalone
      Title: Chief Restructuring Officer

     

      

     

    Get the next $TMBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TMBR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TMBR
    Leadership Updates

    Live Leadership Updates

    See more
    • Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors

      LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST) today announces that it has appointed Michael L. Derby to its Board of Directors. "Michael is a successful pharma industry leader whose extensive involvement in drug repurposing and his passion for developing and commercializing innovative products that positively impact patients' lives will prove to be invaluable as we advance our three lead clinical assets," stated Dr. Roddy Carter, Chairman of the Board of Acasti. "We anticipate benefitting from his perspective and broad experience." Mr. Derby brings more than two decades of experience and a proven track record wit

      3/25/22 7:30:00 AM ET
      $ACST
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Announces Appointment of John Koconis as Chairman of the Board of Directors

      - Edward J. Sitar appointed as Lead Independent Director of the Board - - Company establishes Science and Technology Committee to be chaired by Dr. David Cohen - Basking Ridge, NJ, April 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that Chief Executive Officer John Koconis has been appointed as Chairman of the Board of Directors. The Company also announced that Edward J. Sitar has been appointed as Lead Independent Director of the Board and David Cohen, M.D., will

      4/23/21 8:00:00 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer

      Dr. Mendelsohn has 20+ Years’ Experience in Clinical Development and Medical Affairs WOODCLIFF LAKE, NJ, Jan. 25, 2021 (GLOBE NEWSWIRE) --   via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the appointment of Alan Mendelsohn, M.D., as Chief Medical Officer. Dr. Mendelsohn assumes the roles and responsibilities of Amir Tavakkol, Ph.D., who will be stepping down as the Company’s Chief Scientific Officer.  “We are pleased to welcome Dr. Mendelsohn to our management team. Dr. Mendelsohn

      1/25/21 4:05:00 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Financials

    Live finance-specific insights

    See more
    • Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results

      - Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital ichthyosis, ARCI and XLRI - - Timber has enrolled 50% of patients for pivotal TMB-001 Phase 3 ASCEND clinical trial - WARREN, NJ, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the fourth quarter and year ended December 31, 2022. John Koconi

      3/31/23 4:28:34 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results

      -Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continues to progress; expected to enroll more than 140 patients with moderate to severe Congenital Ichthyosis- BASKING RIDGE, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the third quarter of 2022, ended September 30, 2022. John Koconis, Chairman and Chie

      11/14/22 8:00:00 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results

      Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022  BASKING RIDGE, NJ, May 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter of 2022, ended March 31, 2022. John Koconis, Chairman and Chief Executive Officer of Timber, commented, "Timber's lead asset, TMB-001, continues to progress following the receipt of Fast Track designation late last month, w

      5/12/22 4:10:00 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

      WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the staff of NYSE Regulation (the "NYSE Regulation") has determined to immediately suspend trading in the Company's common stock from NYSE American, LLC (the "NYSE American"). As previously disclosed, the NYSE Regulation notified Timber on November 21, 2023 that, as a result of the voluntary bankruptcy petitions filed under Chapter 11 of the United States Bankruptcy Code by the Company and certain of its

      11/29/23 5:26:24 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE American

      WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-in-possession ("Timber" or the "Company"), today announced that all "first day" motions related to the Company's voluntary Chapter 11 petitions for reorganization filed on November 17, 2023, were approved on an interim basis by the U.S. Bankruptcy Court for the District of Delaware. At the hearing, among other things, the Court approved an initial $3.0 million in interim funding pursuant to a debt

      11/28/23 5:21:07 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

      WARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the NYSE American LLC (the "NYSE American") has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. As previously disclosed, on June 28, 2023, the Company received written notice from the NYSE American that the Company was not in compliance with Sections 1003(a)(i)

      9/18/23 4:05:00 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Timber Pharmaceuticals Inc.

      SC 13G - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

      8/15/22 6:01:57 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Timber Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

      2/14/22 9:40:54 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Timber Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Timber Pharmaceuticals, Inc. (0001504167) (Subject)

      2/4/22 3:39:18 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    SEC Filings

    See more
    • Timber Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

      1/26/24 8:00:46 AM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership

      8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

      1/22/24 7:21:51 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Timber Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Timber Pharmaceuticals, Inc. (0001504167) (Filer)

      12/22/23 4:12:24 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TMBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Koconis John was granted 70,385 shares, increasing direct ownership by 17,596% to 70,785 units

      4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

      8/22/23 7:46:54 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Mendelsohn Alan was granted 35,193 shares, increasing direct ownership by 17,596% to 35,393 units

      4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

      8/22/23 7:45:20 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Lucchese Joseph was granted 35,193 shares

      4 - Timber Pharmaceuticals, Inc. (0001504167) (Issuer)

      8/22/23 7:43:35 PM ET
      $TMBR
      Biotechnology: Pharmaceutical Preparations
      Health Care